Looking Out for Number One 

Tuesday, November 29th, 2011

In a practice known as “Pay for Delay”, pharmaceutical companies like Pfizer pay rivals to avoid introducing cheaper generic versions. Pfizer keeps getting rich selling their full-price drug, the rivals get rich for not doing any work, and patients are stuck covering the bill. Sounds pretty lousy, right?

Worse, Pfizer is working on a new scheme, where they provide their drug at a discount to middlemen. This time around, most customers may not notice, as insured patients will be paying the generic price. Unfortunately, the uninsured will be left in the lurch, and the companies which manufacture generics will be cut out of the equation. With these kinds of business practices, it seems like Pfizer’s slogan could use some tweaking:

Pfizer: Working Together for a Healthier Stock Price.


If you enjoyed this post, get updates via Twitter, Facebook, or RSS.